icon-folder.gif   Conference Reports for NATAP  
 
  The Liver Meeting
San Francisco
November 2018
Back grey_arrow_rt.gif
 
 
 
In a Placebo Controlled 36 Week Phase 2 Trial, Treatment with MGL-3196 Compared to Placebo Results in Significant Reductions in Hepatic Fat (MRI-PDFF), Liver Enzymes, Fibrosis Biomarkers, Atherogenic Lipids, and Improvement in NASH on Serial Liver Biopsy
 
 
  Reported by Jules Levin
AASD 2018 Nov 9-13 SF

1127181

1127182

1127183

1127184

1127185

1127186

1127187

1127188

1127189

11271810